Cargando…
International STakeholder NETwork (ISTNET): creating a developmental neurotoxicity (DNT) testing road map for regulatory purposes
A major problem in developmental neurotoxicity (DNT) risk assessment is the lack of toxicological hazard information for most compounds. Therefore, new approaches are being considered to provide adequate experimental data that allow regulatory decisions. This process requires a matching of regulator...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309915/ https://www.ncbi.nlm.nih.gov/pubmed/25618548 http://dx.doi.org/10.1007/s00204-015-1464-2 |
_version_ | 1782354772216512512 |
---|---|
author | Bal-Price, Anna Crofton, Kevin M. Leist, Marcel Allen, Sandra Arand, Michael Buetler, Timo Delrue, Nathalie FitzGerald, Rex E. Hartung, Thomas Heinonen, Tuula Hogberg, Helena Bennekou, Susanne Hougaard Lichtensteiger, Walter Oggier, Daniela Paparella, Martin Axelstad, Marta Piersma, Aldert Rached, Eva Schilter, Benoît Schmuck, Gabriele Stoppini, Luc Tongiorgi, Enrico Tiramani, Manuela Monnet-Tschudi, Florianne Wilks, Martin F. Ylikomi, Timo Fritsche, Ellen |
author_facet | Bal-Price, Anna Crofton, Kevin M. Leist, Marcel Allen, Sandra Arand, Michael Buetler, Timo Delrue, Nathalie FitzGerald, Rex E. Hartung, Thomas Heinonen, Tuula Hogberg, Helena Bennekou, Susanne Hougaard Lichtensteiger, Walter Oggier, Daniela Paparella, Martin Axelstad, Marta Piersma, Aldert Rached, Eva Schilter, Benoît Schmuck, Gabriele Stoppini, Luc Tongiorgi, Enrico Tiramani, Manuela Monnet-Tschudi, Florianne Wilks, Martin F. Ylikomi, Timo Fritsche, Ellen |
author_sort | Bal-Price, Anna |
collection | PubMed |
description | A major problem in developmental neurotoxicity (DNT) risk assessment is the lack of toxicological hazard information for most compounds. Therefore, new approaches are being considered to provide adequate experimental data that allow regulatory decisions. This process requires a matching of regulatory needs on the one hand and the opportunities provided by new test systems and methods on the other hand. Alignment of academically and industrially driven assay development with regulatory needs in the field of DNT is a core mission of the International STakeholder NETwork (ISTNET) in DNT testing. The first meeting of ISTNET was held in Zurich on 23–24 January 2014 in order to explore the concept of adverse outcome pathway (AOP) to practical DNT testing. AOPs were considered promising tools to promote test systems development according to regulatory needs. Moreover, the AOP concept was identified as an important guiding principle to assemble predictive integrated testing strategies (ITSs) for DNT. The recommendations on a road map towards AOP-based DNT testing is considered a stepwise approach, operating initially with incomplete AOPs for compound grouping, and focussing on key events of neurodevelopment. Next steps to be considered in follow-up activities are the use of case studies to further apply the AOP concept in regulatory DNT testing, making use of AOP intersections (common key events) for economic development of screening assays, and addressing the transition from qualitative descriptions to quantitative network modelling. |
format | Online Article Text |
id | pubmed-4309915 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-43099152015-02-02 International STakeholder NETwork (ISTNET): creating a developmental neurotoxicity (DNT) testing road map for regulatory purposes Bal-Price, Anna Crofton, Kevin M. Leist, Marcel Allen, Sandra Arand, Michael Buetler, Timo Delrue, Nathalie FitzGerald, Rex E. Hartung, Thomas Heinonen, Tuula Hogberg, Helena Bennekou, Susanne Hougaard Lichtensteiger, Walter Oggier, Daniela Paparella, Martin Axelstad, Marta Piersma, Aldert Rached, Eva Schilter, Benoît Schmuck, Gabriele Stoppini, Luc Tongiorgi, Enrico Tiramani, Manuela Monnet-Tschudi, Florianne Wilks, Martin F. Ylikomi, Timo Fritsche, Ellen Arch Toxicol Meeting Report A major problem in developmental neurotoxicity (DNT) risk assessment is the lack of toxicological hazard information for most compounds. Therefore, new approaches are being considered to provide adequate experimental data that allow regulatory decisions. This process requires a matching of regulatory needs on the one hand and the opportunities provided by new test systems and methods on the other hand. Alignment of academically and industrially driven assay development with regulatory needs in the field of DNT is a core mission of the International STakeholder NETwork (ISTNET) in DNT testing. The first meeting of ISTNET was held in Zurich on 23–24 January 2014 in order to explore the concept of adverse outcome pathway (AOP) to practical DNT testing. AOPs were considered promising tools to promote test systems development according to regulatory needs. Moreover, the AOP concept was identified as an important guiding principle to assemble predictive integrated testing strategies (ITSs) for DNT. The recommendations on a road map towards AOP-based DNT testing is considered a stepwise approach, operating initially with incomplete AOPs for compound grouping, and focussing on key events of neurodevelopment. Next steps to be considered in follow-up activities are the use of case studies to further apply the AOP concept in regulatory DNT testing, making use of AOP intersections (common key events) for economic development of screening assays, and addressing the transition from qualitative descriptions to quantitative network modelling. Springer Berlin Heidelberg 2015-01-25 2015 /pmc/articles/PMC4309915/ /pubmed/25618548 http://dx.doi.org/10.1007/s00204-015-1464-2 Text en © The Author(s) 2015 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Meeting Report Bal-Price, Anna Crofton, Kevin M. Leist, Marcel Allen, Sandra Arand, Michael Buetler, Timo Delrue, Nathalie FitzGerald, Rex E. Hartung, Thomas Heinonen, Tuula Hogberg, Helena Bennekou, Susanne Hougaard Lichtensteiger, Walter Oggier, Daniela Paparella, Martin Axelstad, Marta Piersma, Aldert Rached, Eva Schilter, Benoît Schmuck, Gabriele Stoppini, Luc Tongiorgi, Enrico Tiramani, Manuela Monnet-Tschudi, Florianne Wilks, Martin F. Ylikomi, Timo Fritsche, Ellen International STakeholder NETwork (ISTNET): creating a developmental neurotoxicity (DNT) testing road map for regulatory purposes |
title | International STakeholder NETwork (ISTNET): creating a developmental neurotoxicity (DNT) testing road map for regulatory purposes |
title_full | International STakeholder NETwork (ISTNET): creating a developmental neurotoxicity (DNT) testing road map for regulatory purposes |
title_fullStr | International STakeholder NETwork (ISTNET): creating a developmental neurotoxicity (DNT) testing road map for regulatory purposes |
title_full_unstemmed | International STakeholder NETwork (ISTNET): creating a developmental neurotoxicity (DNT) testing road map for regulatory purposes |
title_short | International STakeholder NETwork (ISTNET): creating a developmental neurotoxicity (DNT) testing road map for regulatory purposes |
title_sort | international stakeholder network (istnet): creating a developmental neurotoxicity (dnt) testing road map for regulatory purposes |
topic | Meeting Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309915/ https://www.ncbi.nlm.nih.gov/pubmed/25618548 http://dx.doi.org/10.1007/s00204-015-1464-2 |
work_keys_str_mv | AT balpriceanna internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes AT croftonkevinm internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes AT leistmarcel internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes AT allensandra internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes AT arandmichael internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes AT buetlertimo internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes AT delruenathalie internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes AT fitzgeraldrexe internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes AT hartungthomas internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes AT heinonentuula internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes AT hogberghelena internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes AT bennekoususannehougaard internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes AT lichtensteigerwalter internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes AT oggierdaniela internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes AT paparellamartin internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes AT axelstadmarta internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes AT piersmaaldert internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes AT rachedeva internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes AT schilterbenoit internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes AT schmuckgabriele internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes AT stoppiniluc internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes AT tongiorgienrico internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes AT tiramanimanuela internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes AT monnettschudiflorianne internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes AT wilksmartinf internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes AT ylikomitimo internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes AT fritscheellen internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes |